JP Morgan Chase
NYMX

JP Morgan Chase’s Nymox Pharmaceutical Corp NYMX Stock Holding History

JP Morgan Chase’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,219
Closed -$1.94K – 7888
2023
Q2 		$1.94K Buy
10,219
+2,475
+32% +$974 ﹤0.01% 6343
2023
Q1 		$3K Sell
7,744
-1,611
-17% -$655 ﹤0.01% 6379
2022
Q4 		$3K Sell
9,355
-289
-3% -$105 ﹤0.01% 6280
2022
Q3 		$4K Buy
9,644
+383
+4% +$152 ﹤0.01% 6165
2022
Q2 		$4K Sell
9,261
-2,188
-19% -$2.01K ﹤0.01% 6225
2022
Q1 		$14K Sell
11,449
-632
-5% -$976 ﹤0.01% 6150
2021
Q4 		$15K Sell
12,081
-99
-0.8% -$158 ﹤0.01% 6273
2021
Q3 		$25K Sell
12,180
-24,832
-67% -$44K ﹤0.01% 6005
2021
Q2 		$58K Sell
37,012
-87,329
-70% -$162K ﹤0.01% 5695
2021
Q1 		$276K Sell
124,341
-4,263
-3% -$11.2K ﹤0.01% 5012
2020
Q4 		$318K Buy
128,604
+87,057
+210% +$192K ﹤0.01% 4619
2020
Q3 		$109K Sell
41,547
-1,437
-3% -$4.18K ﹤0.01% 4649
2020
Q2 		$153K Buy
+42,984
New +$136K ﹤0.01% 4395
2020
Q1 		– Sell
-18,930
Closed -$42K – 5847
2019
Q4 		$42K Sell
18,930
-907
-5% -$1.79K ﹤0.01% 5179
2019
Q3 		$37K Buy
19,837
+646
+3% +$1.13K ﹤0.01% 5272
2019
Q2 		$30K Sell
19,191
-7,722
-29% -$13.5K ﹤0.01% 5359
2019
Q1 		$53K Buy
26,913
+1,098
+4% +$2.33K ﹤0.01% 5110
2018
Q4 		$34K Buy
25,815
+18,315
+244% +$33.5K ﹤0.01% 5202
2018
Q3 		$18K Sell
7,500
-2,075
-22% -$6.13K ﹤0.01% 5439
2018
Q2 		$32K Buy
9,575
+218
+2% +$838 ﹤0.01% 5219
2018
Q1 		$40K Buy
9,357
+1,761
+23% +$6.1K ﹤0.01% 4892
2017
Q4 		$25K Buy
+7,596
New +$27.7K ﹤0.01% 5114

Other funds holding NYMX

DDC
DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return
FCFC
First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return
CAM
Cubic Asset Management Boston, Massachusetts $422M AUM 29.18% 1-Year Est. Return
ODIJL
One Day In July LLC Burlington, Vermont $1.25B AUM 12.08% 1-Year Est. Return

JP Morgan Chase's NYMX Position: Q3 2023 in Review

JP Morgan Chase sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2023, closing a stake of 10,219 shares — an estimated $1.94K sold.

JP Morgan Chase first reported a position in NYMX in Q4 2017 and held it in 22 quarters. The position peaked at $318K in Q4 2020. 5 funds tracked by Wall St. Rank hold NYMX as of Q3 2023.

  • JP Morgan Chase reported no remaining Nymox Pharmaceutical Corp position as of Q3 2023 after selling out during the quarter.
  • JP Morgan Chase sold 10,219 Nymox Pharmaceutical Corp shares in Q3 2023, an estimated $1.94K.
  • JP Morgan Chase first reported a position in Nymox Pharmaceutical Corp in Q4 2017 and held it in 22 quarters.
  • JP Morgan Chase's Nymox Pharmaceutical Corp position peaked at $318K in Q4 2020.
  • 5 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2023.

Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.